Zhejiang Huahai Pharmaceutical (600521.SH) Obtains Drug Registration Certificate for Nicorandil Injection

Stock News11-17

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that it has recently received the Drug Registration Certificate for Nicorandil Injection issued by the National Medical Products Administration (NMPA). Nicorandil Injection is indicated for unstable angina pectoris.

Originally developed by Chugai Pharmaceutical Co., Ltd., Nicorandil Injection was first approved in Japan in September 1993, but the original drug has not been imported into China. Currently, domestic manufacturers holding the registration certificate for this drug include Beijing Sihuan Kebao Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group, and Tianjin Tianshi Zhijiao Pharmaceutical Co., Ltd.

According to data from Menet, the domestic market sales of Nicorandil Injection are projected to reach approximately RMB 620 million in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183699156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183699156","market":"other","top_or_hot":-1,"title":"Zhejiang Huahai Pharmaceutical (600521.SH) Obtains Drug Registration Certificate for Nicorandil Injection","media":"Stock News","content":"<p>Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that it has recently received the Drug Registration Certificate for Nicorandil Injection issued by the National Medical Products Administration (NMPA). Nicorandil Injection is indicated for unstable angina pectoris.</p>\n<p>Originally developed by Chugai Pharmaceutical Co., Ltd., Nicorandil Injection was first approved in Japan in September 1993, but the original drug has not been imported into China. Currently, domestic manufacturers holding the registration certificate for this drug include Beijing Sihuan Kebao Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group, and Tianjin Tianshi Zhijiao Pharmaceutical Co., Ltd.</p>\n<p>According to data from Menet, the domestic market sales of Nicorandil Injection are projected to reach approximately RMB 620 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Huahai Pharmaceutical (600521.SH) Obtains Drug Registration Certificate for Nicorandil Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Huahai Pharmaceutical (600521.SH) Obtains Drug Registration Certificate for Nicorandil Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-17 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that it has recently received the Drug Registration Certificate for Nicorandil Injection issued by the National Medical Products Administration (NMPA). Nicorandil Injection is indicated for unstable angina pectoris.</p>\n<p>Originally developed by Chugai Pharmaceutical Co., Ltd., Nicorandil Injection was first approved in Japan in September 1993, but the original drug has not been imported into China. Currently, domestic manufacturers holding the registration certificate for this drug include Beijing Sihuan Kebao Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group, and Tianjin Tianshi Zhijiao Pharmaceutical Co., Ltd.</p>\n<p>According to data from Menet, the domestic market sales of Nicorandil Injection are projected to reach approximately RMB 620 million in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600521","symbol_name":"华海药业","start_time":0,"source_url":"","article_id":"1183699156","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183699156","pubTimestamp":1763370980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that it has recently received the Drug Registration Certificate for Nicorandil Injection issued by the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600521":"华海药业","BK0239":"医药制造","BK0028":"国家队","BK0185":"二线龙头","BK0201":"可转债","BK0188":"融资融券","BK0070":"员工持股","BK0012":"证金概念"},"translate_title":"浙江华海药业（600521.SH）尼可地尔注射液获得药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":1},"content_text":"Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SH) announced that it has recently received the Drug Registration Certificate for Nicorandil Injection issued by the National Medical Products Administration (NMPA). Nicorandil Injection is indicated for unstable angina pectoris.\nOriginally developed by Chugai Pharmaceutical Co., Ltd., Nicorandil Injection was first approved in Japan in September 1993, but the original drug has not been imported into China. Currently, domestic manufacturers holding the registration certificate for this drug include Beijing Sihuan Kebao Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group, and Tianjin Tianshi Zhijiao Pharmaceutical Co., Ltd.\nAccording to data from Menet, the domestic market sales of Nicorandil Injection are projected to reach approximately RMB 620 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183699156","isCrawlerRequest":true}